This segment focuses on the development and commercialization of intravascular lithotripsy (IVL) technology for treating peripheral artery disease (PAD). Research and development efforts are centered on enhancing catheter designs (M5 and S4 catheters) and optimizing IVL delivery for improved outcomes in above-the-knee and below-the-knee PAD. Technologies used include advanced balloon catheter systems and shockwave generation. The therapeutic area is PAD, addressing the challenges of calcified lesions in the arteries of the legs and feet. Patient impact includes improved blood flow, reduced need for revascularization, and enhanced quality of life. Market positioning is strong due to the innovative IVL approach, offering a differentiated solution compared to traditional angioplasty. Future opportunities include expanding the product portfolio and geographic reach. Regulatory and clinical aspects involve ongoing clinical trials and FDA approvals. Partnerships with interventional cardiologists, vascular surgeons, and interventional radiologists are crucial for market penetration.

This segment concentrates on the application of intravascular lithotripsy (IVL) for treating coronary artery disease (CAD). Research and development activities are focused on refining the C2 catheter and IVL delivery systems to address complex calcified lesions in coronary arteries. Technologies employed include shockwave generation and advanced catheter designs. The therapeutic area is CAD, specifically targeting the challenges of severely calcified coronary arteries. Patient impact includes improved vessel preparation, enhanced stent implantation, and reduced risk of adverse cardiac events. Market positioning is strengthened by the innovative IVL approach, offering a unique solution for challenging cases. Future opportunities involve expanding the clinical evidence base and exploring new applications within the coronary space. Regulatory and clinical aspects include ongoing clinical trials and FDA approvals. Collaborations with interventional cardiologists are essential for successful market adoption and clinical practice.